Adaptive Biotechnologies Corp
$ 15.77
-4.25%
06 Feb - close price
- Market Cap 2,425,102,000 USD
- Current Price $ 15.77
- High / Low $ 17.98 / 15.06
- Stock P/E N/A
- Book Value 1.42
- EPS -0.39
- Next Earning Report 2026-02-17
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -0.28 %
- 52 Week High 20.76
- 52 Week Low 6.25
About
Adaptive Biotechnologies Corporation (ADPT) is a cutting-edge biotechnology company headquartered in Seattle, Washington, focused on revolutionizing immune medicine through its proprietary T-cell receptor (TCR) sequencing platform. The company is at the forefront of precision medicine, aiming to enhance the diagnosis and treatment of complex diseases, including cancer and autoimmune disorders. By harnessing the unique capabilities of the immune system, Adaptive is poised to deliver personalized therapeutic solutions that can significantly improve patient outcomes. This commitment to innovative healthcare solutions positions ADPT as an attractive investment opportunity for institutional investors seeking to support advancements in immunotherapy and precision medicine.
Analyst Target Price
$20.86
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-05 | 2025-05-01 | 2025-02-11 | 2024-11-07 | 2024-08-01 | 2024-05-07 | 2024-02-14 | 2023-11-09 | 2023-08-02 | 2023-05-03 | 2023-02-14 |
| Reported EPS | 0.06 | -0.17 | -0.2 | -0.23 | -0.22 | -0.31 | -0.33 | -0.3 | -0.35 | -0.33 | -0.4 | -0.28 |
| Estimated EPS | -0.18 | -0.24 | -0.31 | -0.24 | -0.27 | -0.33 | -0.34 | -0.33 | -0.34 | -0.35 | -0.38 | -0.35 |
| Surprise | 0.24 | 0.07 | 0.11 | 0.01 | 0.05 | 0.02 | 0.01 | 0.03 | -0.01 | 0.02 | -0.02 | 0.07 |
| Surprise Percentage | 133.3333% | 29.1667% | 35.4839% | 4.1667% | 18.5185% | 6.0606% | 2.9412% | 9.0909% | -2.9412% | 5.7143% | -5.2632% | 20% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-17 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.183 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADPT
2026-02-06 22:58:25
Adaptive Biotechnologies (NASDAQ:ADPT) reported strong financial results for Q4 and full-year 2025, with total revenue growing 55% year-over-year. The company's MRD business achieved profitability ahead of expectations, with revenue up 46%, driven by increased clonoSEQ test volumes and ASP expansion. Adaptive also highlighted progress in its Immune Medicine business through data partnerships and strategic focus on AI modeling, projecting positive adjusted EBITDA and free cash flow for the entire company by the end of 2026.
2026-02-06 11:59:54
BTIG has raised its price target for Adeptus Biotechnologies (NASDAQ:ADPT) to $22.00 from $21.00, maintaining a Buy rating. This adjustment follows the company's robust growth in its Minimal Residual Disease (MRD) business, which saw a 54% year-over-year increase in Q4 2025 and 46% for the full year. The company also exceeded analyst expectations for Q4 2025 earnings and revenue, reporting an EPS of -$0.09 and revenue of $71.7 million.
2026-02-05 22:58:25
Adaptive Biotechnologies (ADPT) reported a Q4 loss of $0.09 per share, exceeding the Zacks Consensus Estimate for a loss of $0.19. Despite this, the company missed revenue estimates, posting $71.68 million against an estimated higher figure. The stock's future performance will largely depend on management's outlook, with a current Zacks Rank #3 (Hold) indicating market-aligned performance expectations.
2026-02-05 22:58:25
Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold 42,788 shares of ADPT stock for approximately $799,104, executed through a Rule 10b5-1 trading plan. The sales occurred while ADPT shares have seen a significant 114.91% return over the past year and were near the company's 52-week high. This insider transaction follows Adaptive Biotechnologies reporting robust 2025 financial results and strategic agreements with Pfizer.
2026-02-05 22:29:05
Adaptive Biotechnologies (NASDAQ:ADPT) significantly exceeded Q4 analyst expectations, reporting a loss of $0.09 per share against an estimated $0.18 loss, with revenue jumping 51% to $71.7 million, well above the $59.33 million consensus. The company's MRD business, which accounted for 86% of quarterly revenue, grew 54%. Adaptive Biotechnologies also achieved positive Adjusted EBITDA of $4.1 million for the quarter and projects 2026 MRD business revenue between $255 million and $265 million.
2026-02-05 22:28:48
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) saw its shares surge over 6% after reporting significantly better-than-expected fourth-quarter results and full-year performance for 2025. The biotechnology company posted a smaller loss per share and substantially higher revenue, driven largely by its MRD business. It also provided an optimistic revenue forecast for its MRD business in 2026 and highlighted key operational achievements.
